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Objectives. We sought o examine the eOicacy of dietary supple- 
mentation of L-arginine on endothelium-dependent vasodilation 
in patients with congestive heart failure. 
Background. Endothelial dysfunction, as evidenced by a dimin- 
ished response to such vasodilators as acetylcholine, is well 
defined in patients with heart failure. These responses are im- 
proved by intraarterial infusion with L-arginine. Because L- 
arginine is a semiessential amino acid, we investigated the effects 
of dietary L-arginine on endothelium-dependent vasodilation in 
these patients. 
Methods. Twenty patients with heart failure (New York Heart 
Association functional class III/IV, mean [-+SE] age 51.3 _+ 1.7 
years) and seven healthy control subjects (mean age 52.6 -+ 3.3 
years) were studied. All patients continued taking their usual 
treatment. Responses to acetylcholine and sodium nitroprusside 
were determined using forearm plethysmography. Patients with 
heart failure received either L-arginine (20 g/day every day for 28 
days) or placebo (vehicle syrup in equal amounts) in a double- 
blind protocol. The calculated power of the study was between 62% 
and 80% to detect a 30% to 40% change in area under the 
dose-response (forearm vascular esistance) curve. 
Results. Responses to acetylcholine, but not to sodium nitro- 
prusside, were significantly attenuated in patients with heart 
failure compared with control subjects (mean area under curve 
[AUC], control subjects vs. patients with heart failure: 1,125.4 -+ 
164.5 vs. 617.3 -+ 116.6 U, p < 0.05, by Student t test). A significant 
increase in urea and aspartate transaminase l vels in patients 
receiving active L-arginine treatment was observed. Responses to 
acetylcholine (AUC; before vs. after L-arginine: 641.5 -+ 126.7 vs. 
695.9 -+ 151.9 U) and sodium nitroprusside were not affected by 
either L-arginine or placebo. 
Conclusions. Endothelial dysfunction was apparent in patients 
with heart failure despite rigorous vasoactive treatment. Oral 
administration with L-arginiue was ineffective in influencing en- 
dothelial function in these patients. 
(J Am Coil Cardio11996;27:1207-13) 
Peripheral vasoconstriction is a characteristic feature of con- 
gestive heart failure. This has been attributed to activation of 
the sympathetic nervous ystem (1,2), the renin-angiotensin 
system (3) or the pituitary-vasopressin axis (4). However, 
recent attention has been directed toward a potential contrib- 
utory role of the vascular endothelium. Considerable support 
has accumulated for abnormal endothelium-dependent vaso- 
dilation in heart failure arising from in vivo and in vitro studies 
performed both in humans (5-7) and animals with experimen- 
tal heart failure (8-10). The dysfunction is associated with 
diminished vasodilator responses to acetylcholine and attenu- 
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ated hyperemic responses to exercise and ischemia, both of 
which are largely endothelium dependent (11,12). 
Recently, several groups have shown that infusion of the 
nitric oxide precursor L-arginine can improve endothelium- 
dependent dilation, previously demonstrated to be diminished, 
in hypercholesterolemic humans (13,14). In 1994, Hirooka et 
al. (12) reported that intraarterial infusions of L-arginine en- 
hanced the vasodilator action of acetylcholine and ischemia in 
patients with heart failure. L-Arginine, asemiessential amino acid 
(15) and dietary supplement, is used therapeutically in human 
infants born with carbamyl synthetase deficiency (16) and in 
children with lysinuria (17). Dietary supplementation with L- 
arginine has also been tested in men for reproductive activity (18). 
In the present study we examined the efficacy of orally adminis- 
tered supplemental L-arginine to augment endothelial function in 
patients with severe heart failure. 
Methods  
Subjects. We recruited into our study 20 patients with 
severe heart failure (New York Heart Association functional 
©1996 by the American College of Cardiology 0735-1097/96/$15.00 
Published by Elsevier Science Inc. SSDI 0735-1097(95)00611-7 
1208 CHIN-DUSTING ET AL. JACC Vol. 27, No. 5 
DIETARY L-ARGININE IN HEART FAILURE April 1996:1207-13 
Table 1, Profile and Antifailure Treatment ofPatients With 
Heart Failure 
NYHA 
Pt Age (yr)/ % Functional Antifailure 
No. Gender LVEF Etiology Class Treatment 
1 58/M 26 ICM 4 ACE, D, Di, N 
2 51/M 17 1CM 3 ACE, A, D 
3 35/M 17 DoxCM 3 ACE, A, D, Di 
4 48/M 23 ICM 3 ACE, A, D, Di, N 
5 40/M 21 IDCM 3 ACE, A, D, Di, N 
6 54/M 26 ICM 4 D, Di, A, N 
7 43/M 31 IDCM 2 ACE, A, D, Di 
8 48/M 13 IDCM 3 ACE, A, D, Di 
9 57/M 27 ICM 3 ACE, D, Di, N 
10 57/F 22 ICM 4 ACE, A, D, Di, N 
11 51/M 20 ICM 3 ACE, A, D, Di, N 
12 61/M 30 IDCM 3 ACE, A, D, Di, N 
13 50/M 19 IDCM 3 ACE, A, D, Di 
14 44/M 14 ICM 2 ACE, A, D, Di 
15 47/M 19 IDCM 4 ACE, D, Di 
16 44/M 33 VHD 4 ACE, D 
17 64/M 15 ICM 4 ACE, A, D, Di, N 
18 46/M 15 ICM 3 ACE, A, D, Di, N 
19 57/M 12 ICM 4 ACE, A, D, Di 
20 53/M 15 ICM 3 ACE, A 
A = anticoagulant; ACE = angiotensin-converting e zyme inhibitor; D - 
diuretic; Di = digoxin; DoxCM - doxorubicin cardiomyopathy; ICM -- ischemic 
cardiomyopathy; IDCM = idiopathic dilated cardiomyopathy; LVEF = left 
ventrieular ejection fraction; N = nitrate; NYHA = New York Heart Associa- 
tion; Pt = patient; VHD = valvular heart disease. 
class III/IV, 19 men, 1 woman; mean [_+SE] age 51.3 _+ 1.7 
years) and 7 healthy male control subjects (mean age 52.6 _+ 
3.3 years). All patients with heart failure were awaiting heart 
transplantation a d maintained their usual medication regi- 
men for the duration of the trial (Table 1). All control subjects 
had normal findings on physical examination, as well as routine 
hematologic and biochemical blood analyses. Criteria for entry 
into the study included nonsmoking status, absence of alcohol 
abuse (less than three standard alcohol drinks per day), systolic 
blood pressure <140 mm Hg and diastolic blood pressure 
<90 mm Hg, total serum cholesterol <5.5 mmol/liter and total 
triglyceride <2.0 mmol/liter. Control subjects had no previous 
history of major medical illness (including diabetes or any 
other cardiovascular-related diseases) and were not receiving 
any medication at the time of study. 
The study protocol was approved by the Alfred Group of 
Hospitals Ethics Committee, and written informed consent 
was obtained from all subjects, who were also informed of their 
right to withdraw from the protocol at any time during the 
course of the study. 
Study protocol. Control subjects underwent one forearm 
venous occlusion plethysmography session. Patients with heart 
failure were randomized to one of two groups--those given 
L-arginine or those given the placebo solution. Forearm venous 
occlusion plethysmography was performed before and after 4 
weeks of treatment in this patient group. 
Dietary L-arginine. Patients were randomly allocated in a 
double-blind protocol to receive either L-arginine or placebo. 
Randomization a d preparation ofboth the active (L-arginine) 
and placebo oral solutions were performed by the pharmacy 
department of the Alfred Hospital. Patients were given a 
2-week supply at a time of oral solution. The active (L-arginine) 
solution was 300 g arginine hydrochloride (courtesy of Ajino- 
moto Co., Kawasaki, Japan) added to deionized water (400 ml) 
and compound hydroxybenzoate solution (5 ml) and made up 
to a 900-ml volume with either aromatic or orange syrup. The 
preparation for the placebo oral solution was deionized water 
(600 ml) and compound hydroxybenzoate solution (5 ml) made 
up to a 900-ml volume with either aromatic or orange syrup. 
The purity of L-arginine hydrochloride was >98%. Patients 
were instructed to self-administer 30 ml oral solution two times 
a day. 
Rest blood pressure and plasma biochemical analysis. 
Weekly blood pressure measurements were obtained by the 
same nurse throughout the entire study. Supine blood pressure 
measurements were obtained after 10 min of horizontal rest, 
whereas tanding blood pressure measurements were obtained 
after 5 min in the upright position. Blood pressure values were 
obtained at the same time, as closely as possible, on the same 
day of each week at week 0 (pretreatment) through weeks 1, 2, 
3 and 4 (final week of treatment). 
After blood pressure measurements had been taken, 10 ml 
blood was obtained for plasma analysis of urea, creatinine, 
liver function enzymes and electrolyte l vels. 
Walk test. Each patient performed a walk test (19) before 
and after 4 weeks of supplementation with the oral solution. 
Patients were instructed to walk on a flat surface at a self-set 
pace for 6 rain. They were supervised by a cardiologist or a 
trained critical care nurse, both of whom had no knowledge of 
the patient's treatment. The distance walked over the 6-rain 
period was measured. 
Forearm venous occlusion plethysmography. Subjects rested 
supine throughout the course of the experiment in a comfort- 
able, relaxing environment maintained ata constant tempera- 
ture of 22°C. Measurements of forearm blood flow were taken 
in all participants before the introduction of any dietary 
supplementation (day 1) and in patients with heart failure on 
day 29, after 28 days of dietary supplementation with either 
L-arginine or placebo. 
The protocol for measurement of forearm blood flow has 
previously been described (20,21). In summary, forearm blood 
flow was measured by venous occlusion plethysmography with 
a sealed, alloy-filled (gallium and indium), double-strand strain 
gauge (Medasonic). Venous occlusion pressure was 40 to 
50 mm Hg at the proximal end (elbow) and cuff occlusion 
pressure was -200 mm Hg at the distal end (wrist) to arrest all 
circulation to the hand. The distal cuff was inflated before 
determination f forearm blood flow and left inflated for the 
duration of all measurements. Forearm blood flow was calcu- 
lated for 10 of every 20 s. 
The brachial artery was cannulated (3F, 5-cm catheter, 
Cook) for intraarterial blood pressure recordings as well as for 
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Figure 1. Top left, Forearm blood flow responses to 
acetylcholine relative to forearm basal blood flow 
measurements for control (C) and heart failure (HF) 
patient groups. *p < 0.05 versus control group by 
multivariate analysis of variance followed by Student 
t test with Bonferroni correction. Histograms depict 
mean area under the acetylcholine dose-response 
curve. *p < 0.05 versus control group by Student 
test. Bottom left, Forearm vascular esistance re- 
sponses calculated for acetylcholine r lative to fore- 
arm basal resistance measurements for control and 
heart failure groups. *p < 0.05 versus control group 
using multivariate analysis of variance followed by 
Student t test with Bonferroni correction. Histo- 
grams depict mean area (given a negative value to 
depict a decrease in vascular esistance) under the 
acetylcholine dose-response curve. *p < 0.05 versus 
control group using Student test. Top right, Fore- 
arm blood flow responses to sodium nitroprusside 
relative to forearm basal blood flow measurements 
for control and heart failure groups. Histograms 
depict mean area under the sodium nitroprusside 
dose-response curve. Bottom right, Forearm vascu- 
lar resistance responses calculated for sodium nitro- 
prusside relative to forearm basal resistance mea- 
surements for control and heart failure groups. 
Histograms depict mean area (given a negative value 
to depict a decrease invascular esistance) under the 
sodium nitroprusside dose-response curve. Open 
circles = control group (n = 7); solid circles = heart 
failure group (n = 20). 
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local, sequential infusions of acetylcholine (4.6, 9.25, 18.5 
and 37 /xg/min) and sodium nitroprusside (0.2, 0.4, 0.8 and 
1.6 /zg/min). Basal blood flow (the average of three flow 
measurements before each drug infusion) was obtained after 
an equilibration period of 40 to 60 s. Each drug was infused at 
2 ml/min over a maximum of 5 rain or until the response over 
three flow measurements reached a plateau (usually by 3 rain). 
Rest periods of 5 min between concentrations and of 15 rain 
between drugs were observed. At the concentrations used, 
neither systemic blood pressure, recorded with a disposable 
physiologic pressure transducer (Model CMS-327, Biosen- 
sors), nor heart rate, recorded with a lead II electrocardiogram 
(Spacelabs Inc.) was affected. 
Forearm vascular esistance (FVR) was calculated as fol- 
lows: FVR (R units) = Mean arterial pressure (ram Hg)/ 
Forearm blood flow (ml/dl per min). 
Other drugs. Acetylcholine chloride (BDH Chemicals 
Ltd.) was diluted under sterile conditions with 0.9% saline. 
Sodium nitroprusside (David Bull Laboratories) was diluted 
under sterile conditions in 5% dextrose. 
Statistical analysis. Unless otherwise stated, all results are 
expressed as mean value _+ SE. Analysis of variance 
([ANOVA] one or two way or repeated measures where appro- 
priate) followed by a Student test (paired, where appropriate) 
was used. Analysis was performed using SigmaStat Statistical 
Software (Jandel Scientific), which inherently analyzes data for 
normality before performing parametric analysis. Where data 
failed to meet normality criteria, nonparametric analysis (Kruskal 
Wallis nonparametric test) was applied. In addition, analysis for 
each dose-response curve was undertaken by calculation of the 
area under each individual dose-response curve, which was used 
as a single-value summary for that data set (22). 
Resu l ts  
Forearm venous occlusion plethysmography: patients with 
heart failure versus control subjects. Mean basal forearm 
blood flow did not differ (1.93 _+ 0.18 vs. 2.57 -~ 0.47 ml/dl per 
rain, p > 0.05) but mean basal arterial pressure was signifi- 
cantly lower in patients with heart failure than control subjects 
(78.86 _+ 1.75 vs. 93.03 _+ 2.15 mm Hg, p < 0.05 by Student 
test). Mean arterial pressures were not significantly altered in 
the presence of the agonists used (p > 0.05, ANOVA). 
We previously showed (20) a high intrasubject oefficient of 
variation on basal forearm blood flow and vascular esistance. 
Hence, responses to both acetylcholine and sodium nitroprus- 
side were normalized for basal forearm flow (or resistance) 
(i.e., that obtained immediately before each drug addition). 
Both forearm blood flow (area under curve [AUC], control vs. 
heart failure group: 2,019.8 _+ 441.7 vs. 969.0 _+ 238.3 U, p < 
0.05 by Student test) and forearm vascular esistance (AUC, 
control vs. heart failure group: 1,125.4 _+ 164.5 vs. 617.3 + 
116.6 U, p < 0.05 by Student test) responses to acetylcholine 
(Fig. 1), but not to sodium nitroprusside (AUC [forearm blood 
flow], control vs. heart failure group: 173,486 _ 23,657 vs. 
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Figure 2. Top left, Forearm blood flow responses to
acetylcholine r lative to forearm basal blood flow 
measurements for heart failure group before and 
after dietary supplementation with 20 g/day L- 
arginine. Histograms depict mean area under the 
acetylcholine dose-response curve. Bottom left, 
Forearm vascular resistance r sponses calculated for 
acetylcholine r lative to forearm basal resistance 
measurements for heart failure group before and 
after dietary supplementation with 20 g/day L- 
arginine. Histograms depict mean area (given a 
negative value to depict a decrease in vascular resis- 
tance) under the acetylcholine dose-response curve. 
Top right, Forearm blood flow responses tosodium 
nitroprusside r lative to forearm basal blood flow 
measurements for heart failure group before and 
after dietary supplementation with 20 g/day L- 
arginine. Histograms depict mean area under the 
sodium nitroprusside ose-response curve. Bottom 
right, Forearm vascular resistance r sponses calcu- 
lated for sodium nitroprusside r lative to forearm 
basal resistance measurements for heart failure 
group before and after dietary supplementation with 
20 g/day L-arginine. Histograms depict mean area 
(given a negative value to depict a decrease in
vascular resistance) under the sodium nitroprusside 
dose-response curve. Analysis by repeated-measures 
two-way analysis of variance or Student paired t test 
where appropriate. Open circles = before L-arginine 
(n = 9); solid circles = after L-arginine. 
147,768 _ 26,555 U; p > 0.05 by Student test), were 
significantly depressed in patients with heart failure. 
Dietary L-arginine. Adverse events. After randomization 
into one of the two groups, three patients withdrew from the 
dietary protocol. One patient (Patient 1, Table 1) was receiving 
the active oral u-arginine supplement, whereas the other two 
(Patients 11 and 12) were receiving the placebo. Patient 1 
developed unstable angina 3 to 4 days after commencement of 
the active supplement. Blood pressure dropped from 
120/80 mm Hg to 90/60 mm Hg during this time. Patient 11 
withdrew from the study to undergo heart transplantation. 
Patient 12 developed atrial flutter (slow 200 beats/min with 
2:1 atrioventricular block) 3 days after commencement of he 
oral supplement. He also complained of lightheadedness, 
nausea, lethargy and postural dizziness. Thus, a total of 17 
patients completed the L-arginine trial--9 receiving active 
supplement and 8 receiving placebo. 
Of the nine patients who remained on the L-arginine 
supplement, one complained of diarrhea, nausea nd malaise; 
another of diarrhea and stomach cramps; and a third of 
diarrhea. Of the eight patients who remained on the placebo, 
one complained of muscle pain in the back and abdominal 
areas; one of nausea nd diarrhea; another of nausea; and a 
fourth of gastrointestinal upset leading to flatus. Two patients 
on the oral L-arginine supplement claimed to feel much better, 
as did two patients on the placebo. 
Plasma biochemistry. Plasma urea levels increased signifi- 
cantly in heart failure patients receiving L-arginine supplemen- 
tation. These levels increased from pretreatment levels of 
8.33 + 1.06 to 12.82 _+ 1.75 mmol/liter in week 1 and remained 
elevated throughout the 4 weeks of supplementation. Plasma 
urea levels were not altered by placebo supplementation. 
Neither plasma glucose nor plasma electrolyte (sodium, 
potassium, chloride and bicarbonate) levels were altered ur- 
ing the 4 weeks of treatment with either t:arginine or placebo. 
There was a small but significant increase in aspartate ransam- 
inase levels in the L-arginine group (from 25.90 _+ 2.49 U/liter 
in week 0 to 32.00 _+ 2.59 U/liter in week 3), but not in the 
placebo group. Protein levels fluctuated significantly during the 
4 weeks in both the L-arginine and placebo groups. 
Rest blood pressure. Neither dietary L-arginine nor placebo 
supplementation had an effect on supine systolic or diastolic or 
standing systolic or diastolic blood pressures. 
Forearm venous occlusion plethysmography. Figure 2 shows 
forearm blood flow and calculated vascular resistance re- 
sponses to acetylcholine in patients with congestive heart 
failure. Dietary L-arginine had no effect on either of these 
values or on responses to sodium nitroprusside (AUC [forearm 
blood flow] before vs. after L-arginine: 152,604 _+ 49,636 vs. 
183,461 _+ 65,881 U; p > 0.05 by Student paired t test). 
Likewise, the placebo supplement had little effect on mean 
basal blood flow and vascular esistance and on responses to 
acetylcholine and sodium nitroprusside. 
Intergroup comparisons were also undertaken (i.e., re- 
sponses of patients after placebo vs. patients after L-arginine 
supplementation). There was no difference in basal values or 
responses to acetylcholine or sodium nitroprusside between 
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these two groups. Formal analysis of results was described in 
the Statistical Analysis section previously. 
Six-minute walk test. Dietary L-arginine had little effect on 
the capacity of the patients to perform the walk test. The 
distance walked in 6 min after I_-arginine supplementation was 
500.0 _+ 79.6 m compared with 467.4 _+ 54.3 m before 
supplementation (p > 0.05 by paired t test). The distance 
walked before and after placebo supplementation was 396.5 _+ 
67.0 and 401.2 _+ 68.1 m, respectively (p > 0.05 by paired t 
test). 
Discuss ion 
The two primary findings are that 1) endothelium- 
dependent vasodilation, as assessed by responses to acetylcho- 
line, is impaired in patients with severe heart failure despite 
vigorous conventional vasoactive medication, and 2) dietary 
supplementation f the nitric oxide precursor, L-arginine 20 
g/day for 28 days, has no effect on this dysfunction in these 
patients. 
Since the original report (5) that endothelium-dependent 
vasodilation is defective in patients with heart failure, several 
authors have pursued and confirmed this finding (6,12,23,24). 
In all previous studies, however, vasoactive treatment was 
withheld for several days before the day of study. Our study 
shows that this impairment isstill present despite conventional 
vasoactive medication i  patients with end-stage heart failure. 
Causes of endothelial dysfunction in heart failure. Al- 
though it is accepted that heart failure is associated with 
impaired endothelium-dependent dilation, the cause of this 
dysfunction is not well described. It is reported not to be 
associated with age, plasma levels of norepinephrine or renin 
activity in this patient group (5). It is unlikely to be associated 
with atherosclerosis because upper limb vessels, such as those 
in the forearm, are seldom involved, or with hypercholesterol- 
emia because impaired endothelium-dependent dilation has 
been reported in heart failure patients despite normal plasma 
total cholestol levels (mean 188.4 + 8.82 mg/dl) (12). Much of 
the human data has been limited to muscarinic stimulation of 
endothelium nitric oxide release, confirming an impaired re- 
sponse to either acetylcholine or methacholine (5,6,12,24). 
However, responses to substance P, another endothelium- 
dependent vasodilator, have been reported not to be altered in 
patients with heart failure (24), leading to the suggestion that 
muscarinic receptors or the postreceptor mechanism coupled 
with muscarinic receptors are selectively altered in this disease 
state. In contrast, responses to reactive hyperemia re blunted 
in these patients (12). This supports our findings in a rabbit 
model of heart failure, where responses to adenosine, the 
major metabolite released during ischemia, were similarly 
blunted (10). Although the mechanism by which adenosine 
causes vasodilation remains controversial, with evidence for 
endothelium-dependent vasorelaxation (25) as well as direct, 
endothelium-independent, smooth muscle vasodilatory prop- 
erties (26,27), it is unlikely that the endothelial dysfunction 
seen in heart failure is limited to the muscarinic receptor. 
Because only forearm vascular responses to acetylcholine were 
used for the evaluation of endothelial function in the current 
study, it is not known whether other vascular esponses would 
have been affected by L-arginine supplementation. However, 
because intraarterial infusions of this amino acid improved 
both responses to acetylcholine as well as to reactive hyper- 
emia (12), it is unlikely that other indexes of endothelial 
function would have been influenced in the present study. 
Supplementation with L-arginine. Because intraarterial in- 
fusion with the nitric oxide precursor, L-arginine (28), effec- 
tively reverses the blunted endothelium-dependent vasodila- 
tion in the forearm arteries of patients with heart failure (12), 
it may be construed that regardless of the underlying cause, 
loading the endothelium with exogenous substrate can over- 
come the impairment. Whether this effect is simply due to 
repleting a limited substrate pool is controversial because 
infusions of L-arginine augment acetylcholine r sponses in the 
forearms of healthy humans (29). Because the intracellular 
concentration of L-arginine is estimated to be -100/~mol/liter 
(30) and the K m of nitric oxide synthase for L-arginine is 
<10 /~mol/liter (31), the hypothesis regarding repletion of 
substrate isarguable. Regardless, the failure of oral L-arginine 
to influence acetylcholine responses in the current study 
reflects not on the ineffectiveness of L-arginine itself because 
intraarterial infusions of L-arginine have been proved effective 
(12), but on the ineffectiveness of the oral route of adminis- 
tration. 
Effects of dietary L.arginine in heart failure. Although it is 
arguable whether dietary arginine is indispensable in adult 
humans, Rose's (15) classification of L-arginine as a semies- 
sential amino acid is still commonly used. In infants with 
carbamyl phosphate synthetase deficiency, an arginine- 
deficient syndrome (16), growth retardation can be overcome 
by the addition of 400 mg arginine to the daily diet. Similarly, 
children with lysinuria (17) or argininosuccinase d ficiency 
(32) require dietary arginine for normal growth and develop- 
ment. Dietary supplementation f L-arginine has also been 
used in clinical trials for improvement ofmale spermatogenesis 
(18,33). Although evidence to date suggests that high doses of 
arginine supplementation (30 to 60 g) are well tolerated in 
humans (17), two cases of severe hyperkalemia, one leading to 
fatal arrhythmia (34), after supplementation at these doses 
have been reported. Both patients, however, had renal and 
hepatic insufficiency. In light of this and in view of a chronic 
oral supplementation, the dose of 20 g/day was chosen for the 
current study. 
There is a paucity of data available on the metabolic fate of 
intragastric L-arginine in humans. The uptake of arginine by 
the liver from the systemic circulation is reported to be 
relatively poor owing to the low activity of the transport system 
responsible for transmembrane passage of the cationic amino 
acids arginine, lysine and ornithine in hepatocytes (35). Intes- 
tinal absorption of arginine also shares a transport system with 
lysine, ornithine and cysteine (36) and may likewise be rela- 
tively poor. Also, the conversion of dietary arginine within the 
splanchnic region accounts for 16% of daily NO 3 formation 
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(37), suggesting a significant first-pass disappearance. The fate 
of supranormal doses of dietary supplementation f this amino 
acid, such as that used in this study, is not known. However, 
underscoring the importance of the liver urea cycle and rapid 
portal vein absorption of arginine through intraperitoneal or
intrasplenic njections was efficacious against ammonia toxicity 
in rats, whereas oral administration offered minimal protection 
(38). Hence, although plasma urea levels were significantly 
elevated in the current study, it is possible that there was not a 
proportional increase in plasma arginine owing to its signifi- 
cant first-pass metabolism in the liver. 
Plasma L-arginine concentrations were not obtained in the 
current study. In a recent study (39), oral L-arginine given to 
healthy individuals (7 g three times daily for 3 days) resulted in 
elevated plasma L-arginine levels, from 129 _+ 7 to 303 
/xmol/liter. Although platelet aggregation was significantly 
inhibited in that study, endothelium-dependent vasodilation 
was not affected in those healthy volunteers. The lack of 
confirmatory medication compliance in the absence of plasma 
L-arginine measurements in the current study is deflected in 
part by the significant increase in plasma urea levels seen in 
patients administered the active supplement, but not the 
placebo. At 20 g/day, L-arginine increased plasma urea levels 
significantly in this patient group from the first week of 
treatment. These levels remained high throughout the dura- 
tion of the study, exceeding the maximal normal value of 8.5 
mmol/liter. Plasma liver enzyme levels of aspartate transami- 
nase also increased significantly with L-arginine treatment, 
although these did not extend beyond normal values. Plasma 
electrolyte levels, including potassium, were not affected by 
either treatment. Hence, although plasma L-arginine levels 
were not measured inthe current study, which makes it difficult 
to know if the patients were taking effective amounts of 
arginine supplementation in terms of reversal of endothelial 
dysfunction, it is likely that 20 g/day k-arginine is close to the 
maximal clinically tolerable dose in these patients, since higher 
dose would be expected to further exacerbate plasma urea and 
aspartate transaminase l vels. The patients' ability to perform 
physical exercise, as assessed by the walk test, was unaltered by 
either treatment. Other adverse signs and symptoms were not 
formally assessed. 
Conclusions. Although endothelium-dependent vasodila- 
tion is markedly impaired in patients with heart failure despite 
vigorous conventional vasoactive treatment, oral supplementa- 
tion with L-arginine, aimed at restoring endothelium nitric 
oxide function, was unsuccessful. Although it is possible that 
insufficient e-arginine was given in the current study owing to 
inadequate dosing, poor absorption or a large first-pass disap- 
pearance, a daily dose of 20 g/day appears to be close to the 
maximal clinically tolerated ose in these patients. The rela- 
tively small number of patients studied in this placebo- 
controlled study also raises the question of the adequacy of 
statistical power. The calculated power of the study (placebo- 
controlled, paired data, n = 9) is between 62% and 80% to 
detect a 30% to 40% change in (derived) area under the dose 
(acetylcholine)-response (forearm vascular esistance) curve. 
This calculation isbased on the findings of Hirooka et al. (12), 
who found a 30% to 40% increase in this parameter after 
intraarterial e-arginine, and on our calculated standard evia- 
tion of 35% for this parameter. It is acknowledged that the 
statistical power of this study is weaker than the ideal, and that 
the negative outcome must therefore be accepted with some 
caution. Another point for consideration is the previous find- 
ing that the degree of endothelial function improvement by 
k-arginine is inversely proportional to the severity of the 
disease (40). All the patients tudied in this trial had end-stage 
heart failure and were awaiting transplantation. Had a patient 
group with mild heart failure been studied, the endothelial 
dysfunction may well have been reversible with the treatment 
regimen given. Nevertheless, on the basis of the current 
findings, we conclude that oral supplementation with k- 
arginine is unlikely to be of practical clinical benefit o patients 
with severe heart failure. 
We are grateful to Sisters Leonie Johnston and Sue Tamblyn for their nursing 
assistance. L-Arginine monohydrochloride was generously donated by Ajinomoto 
Co., Kawasaki, Japan, 
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